Research Paper Volume 15, Issue 16 pp 8204—8219
PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer
Figure 3. Clinical and molecular features of ATRX, PTPRD, and PTPRT in advanced NSCLC with ICIs treatment. (A) The prevalence of ATRX, PTPRD, and PTPRT mutations in the third cohort (MSKCC, Nat Genet 2019). (B) PTPRD was related to the PFS and OS. (C) PTPRT was related to the PFS. (D) ATRX was related to the PFS. (E–G) ATRX, PTPRD, and PTPRT mutations were closely related to higher TMB value.